scholarly journals Osseous Metaplasia in Low-grade Ovarian Serous Carcinoma With a BRAF Mutation

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Xavier Catteau ◽  
Fanny Preat ◽  
Nicky D’haene ◽  
Jean-Christophe Noël
Keyword(s):  
Braf Mutation ◽  
Serous Carcinoma ◽  
Osseous Metaplasia ◽  
Low Grade ◽  
Ovarian Serous Carcinoma

Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?

2015 ◽  
Vol 25 (7) ◽  
pp. 1201-1207 ◽  
Author(s):  
Esther Louise Moss ◽  
Tim Evans ◽  
Philippa Pearmain ◽  
Sarah Askew ◽  
Kavita Singh ◽  
...  
Keyword(s):  
Overall Survival ◽  
Clear Cell ◽  
Stage Iii ◽  
Serous Carcinoma ◽  
Low Grade ◽  
Type I ◽  
High Grade ◽  
Type Ii ◽  
Ovarian Serous Carcinoma ◽  
Significant Difference

IntroductionThe dualistic theory of ovarian carcinogenesis proposes that epithelial “ovarian” cancer is not one entity with several histological subtypes but a collection of different diseases arising from cells of different origin, some of which may not originate in the ovarian surface epithelium.MethodsAll cases referred to the Pan-Birmingham Gynaecological Cancer Centre with an ovarian, tubal, or primary peritoneal cancer between April 2006 and April 2012 were identified from the West Midlands Cancer Registry. Tumors were classified into type I (low-grade endometrioid, clear cell, mucinous, and low-grade serous) and type II (high-grade serous, high-grade endometrioid, carcinosarcoma, and undifferentiated) cancers.ResultsOvarian (83.5%), tubal (4.3%), or primary peritoneal carcinoma (12.2%) were diagnosed in a total of 583 woman. The ovarian tumors were type I in 134 cases (27.5%), type II in 325 cases (66.7%), and contained elements of both type I and type II tumors in 28 cases (5.7%). Most tubal and primary peritoneal cases, however, were type II tumors: 24 (96.0%) and 64 (90.1%), respectively. Only 16 (5.8%) of the ovarian high-grade serous carcinomas were stage I at diagnosis, whereas 240 (86.6%) were stage III+. Overall survival varied between the subtypes when matched for stage. Stage III low-grade serous and high-grade serous carcinomas had a significantly better survival compared to clear cell and mucinous cases,P= 0.0134. There was no significant difference in overall survival between the high-grade serous ovarian, tubal, or peritoneal carcinomas when matched for stage (stage III,P= 0.3758; stage IV,P= 0.4820).ConclusionsType II tumors are more common than type I and account for most tubal and peritoneal cancers. High-grade serous carcinomas, whether classified as ovarian/tubal/peritoneal, seem to behave as one disease entity with no significant difference in survival outcomes, therefore supporting the proposition of a separate classification of “tubo-ovarian serous carcinoma”.

Cancer Stem Cell–Related Marker NANOG Expression in Ovarian Serous Tumors: A Clinicopathological Study of 159 Cases

2017 ◽  
Vol 27 (9) ◽  
pp. 2006-2013 ◽  
Author(s):  
Nataša Kenda Šuster ◽  
Snježana Frković Grazio ◽  
Irma Virant-Klun ◽  
Ivan Verdenik ◽  
Špela Smrkolj
Keyword(s):  
Stem Cell ◽  
Cancer Stem Cell ◽  
Signal Intensity ◽  
Serous Carcinoma ◽  
Low Grade ◽  
Clinical Parameters ◽  
High Grade ◽  
Ovarian Serous Carcinoma ◽  
Nanog Expression ◽  
Serous Tumors

ObjectiveThe objectives of this study were to assess cancer stem cell–related marker NANOG expression in ovarian serous tumors and to evaluate its prognostic significance in relation to ovarian serous carcinoma.MethodsNANOG protein expression was immunohistochemically evaluated in the ovarian tissue microarrays of 20 patients with benign ovarian serous tumors, 30 patients with borderline ovarian serous tumors, and 109 patients with ovarian serous carcinomas, from which 106 were of high-grade and 3 of low-grade morphology Immunohistochemical reaction was scored according to signal intensity and the percentage of positive cells in tumor samples. Pursuant to our summation of signal intensity and positive cell occurrence, we divided our samples into 4 groups: NANOG-negative, NANOG–slightly positive, NANOG–moderately positive, and NANOG–strongly positive group. Complete clinical data were obtained for the ovarian serous carcinoma group, and correlation between clinical data and NANOG expression was analyzed.ResultsA specific brown nuclear, or cytoplasmic reaction, was considered a positive NANOG staining. In terms of the ovarian serous carcinoma group, 69.7% were NANOG positive, 22.9% slightly positive, 22.9% moderately positive, and 23.9% strongly positive. All NANOG-positive cases were of high-grade morphology. Benign and borderline tumors and low-grade serous carcinomas were NANOG negative. There was no significant correlation between NANOG expression and clinical parameters in terms of the ovarian serous carcinoma group.ConclusionsPositive NANOG expression is significantly associated with high-grade ovarian serous carcinoma and is absent in benign, borderline, and low-grade serous lesions. In our study, there was no correlation between NANOG expression and clinical parameters, including its use in the prognosis of ovarian serous carcinoma.

scholarly journals Low-grade serous carcinoma with extensive osseous metaplasia arising from ovarian serous cystadenofibroma

2021 ◽  
Vol 36 ◽  
pp. 100707
Author(s):  
Renan Ribeiro e Ribeiro ◽  
Ashley Valenzuela ◽  
Lindsey Beffa ◽  
C. James Sung ◽  
M. Ruhul Quddus
Keyword(s):  
Serous Carcinoma ◽  
Osseous Metaplasia ◽  
Low Grade

scholarly journals Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma

2003 ◽  
Vol 95 (6) ◽  
pp. 484-486 ◽  
Author(s):  
G. Singer ◽  
R. Oldt ◽  
Y. Cohen ◽  
B. G. Wang ◽  
D. Sidransky ◽  
...  
Keyword(s):  
Serous Carcinoma ◽  
Low Grade ◽  
Ovarian Serous Carcinoma

Low-grade ovarian serous carcinoma metastasis to the maxilla

Oral Surgery ◽  
2018 ◽  
Vol 11 (4) ◽  
pp. 329-334
Author(s):  
S. Tocaciu ◽  
C. Fiddler ◽  
N. Krzys ◽  
E. Long ◽  
I. Chambers
Keyword(s):  
Serous Carcinoma ◽  
Low Grade ◽  
Ovarian Serous Carcinoma ◽  
Carcinoma Metastasis

High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour

2007 ◽  
Vol 50 (6) ◽  
pp. 773-779 ◽  
Author(s):  
C J O'Neill ◽  
H A McBride ◽  
L E Connolly ◽  
M T Deavers ◽  
A Malpica ◽  
...  
Keyword(s):  
Serous Carcinoma ◽  
Low Grade ◽  
High Grade ◽  
Ovarian Serous Carcinoma ◽  
Borderline Tumour ◽  
P16 Expression

Maximal cytoreduction is related to improved disease-free survival in low-grade ovarian serous carcinoma

2019 ◽  
Vol 105 (3) ◽  
pp. 259-264 ◽  
Author(s):  
Gunsu Kimyon Comert ◽  
Osman Turkmen ◽  
Cigdem Guler Mesci ◽  
Alper Karalok ◽  
Ozge Sever ◽  
...  
Keyword(s):  
Surgical Outcomes ◽  
Residual Disease ◽  
Disease Free Survival ◽  
Disease Stage ◽  
Serous Carcinoma ◽  
Low Grade ◽  
Free Survival ◽  
Ovarian Serous Carcinoma ◽  
Increased Risk ◽  
Disease Free

Objective: To evaluate the factors predicting oncologic outcomes in low-grade ovarian serous carcinoma (LGOSC). Methods: Seventy patients with LGOSC were included in the study. According to the residual disease present at the end of the initial cytoreductive surgery (CRS), surgical outcomes are defined as follows: maximal CRS for absence of macroscopic residual tumors, optimal CRS for macroscopic residual tumors with diameters ranging from 0.1 to ⩽1 cm diameter, and suboptimal CRS for macroscopic residual tumors measuring >1 cm in diameter. Results: Five-year disease-free survival (DFS) and cancer-specific survival (CSS) were 61% and 83%, respectively. Surgical outcomes were suboptimal in 3 (4.3%) patients, optimal in 8 (11.4%) patients, and maximal in 59 (84.3%) patients. Stage and surgical outcomes were related to DFS ( p < 0.05). Compared with maximal CRS, the presence of residual tumors (suboptimal and optimal debulking) was related to threefold increased risk of disease failure (recurrence or progression) (hazard ratio [95% confidence interval] 3.00 [1.27–7.09]; P=0.012). CSS was associated with disease stage alone ( P=0.03). Advanced stage was related with lower DFS and CSS. Conclusions: Maximal CRS facilitates an improvement in DFS. Achieving no residual disease after the completion of surgery should be a cornerstone of LGOSC management.

Sign in / Sign up

Export Citation Format

Share Document